The use of low-molecular-weight heparins in outpatient oral surgery for patients receiving anticoagulation therapy

Journal of the American Dental Association

Volumn 133, Issue 8, 2002, Pages 1083-1087

  Johnson Leong, Charmaine ^b   Rada, Robert E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

AGED; AMBULATORY SURGERY; ARTICLE; CASE REPORT; DENTAL CARE; DRUG COST; ECONOMICS; HUMAN; MALE; ORAL SURGERY; SUBCUTANEOUS DRUG ADMINISTRATION; TOOTH EXTRACTION; VEIN THROMBOSIS;

AGED; ALVEOLOPLASTY; AMBULATORY SURGICAL PROCEDURES; ANTICOAGULANTS; DENTAL CARE FOR CHRONICALLY ILL; DRUG COSTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; ORAL SURGICAL PROCEDURES; TOOTH EXTRACTION; VENOUS THROMBOSIS;

EID: 0036691620     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2002.0333     Document Type: Article

References (31)

1. Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med 1998;158(15):1610-6.
2. Campbell J, Alvarado F, Murray R. Anticoagulation and minor oral surgery: should the anticoagulation regimen be altered? J Oral Maxillofac Surg 2000;58(2):131-5.
3. Webster K, Wilde J. Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations. Br J Oral Maxillofac Surg 2000;38(2):124-6.
4. Stringer KA. Emergence of low molecular weight heparins in cardiology. Pharmacotherapy 1999;19:141S-6S.
5. Wahl MJ, Howell J. Altering anticoagulation therapy: a survey of physicians. JADA 1996;127:625-34.
6. Rydberg EJ, Westfall JM, Nicholas RA. Low-molecular-weight-heparin in preventing and treating DVT. Am Fam Physician 1999; 59(6):1607-12.
7. Aguilar D, Goldhaber SZ. Clinical uses of low molecular weight heparins. Chest 1999;115:1418-23.
8. Lev-Ran O, Kramer A, Gurevitch J, Shapira I, Mohr R. Low-molecular-weight heparin for prosthetic heart valves: treatment failures. Ann Thorac Surg 2000;69:264-6.
9. Hirsh J, Bates SM. The emerging role of low-molecular weight heparin in cardiovascular medicine. Prog Cardiovasc Dis 2000;42(4): 235-46.
10. Turpie AG. New therapeutic opportunities for heparins: what does low molecular weight heparin offer? J Thromb Thrombolysis 1996;3(2):145-9.
11. Singer IO, Tait RC, Murdoch D. Low-molecular-weight heparin as optimal solution to therapeutic heparinization. Am Heart J 2000; 139(3):558-61.
12. Hirsh J. From bench to bedside: history of development of LMWHs. Orthop Rev 1994;I(supplement):40-6.
13. Todd DW, Roman A. Outpatient use of low-molecular weight heparin in an anticoagulated patient requiring oral surgery: case report. J Oral Maxillofac Surg 2001;59:1090-2.
14. Hull R, Pineo G, Stein P. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: the twilight of anticoagulant monitoring. Int Angiol 1998;17:213-24.
15. O'Brien B, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999;159:2298-304.
16. O'Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000;139:423-9.
17. Estrada CA, Mansfield CJ, Heudebert GR. Cost-effectives of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. J Gen Intern Med 2000;15(2):108-15.
18. Meehan S, Schmidt MC, Mitchell PF. The International Normalized Ratio as a measure of anticoagulation: significance for the management of the dental outpatient. Spec Care Dentist 1997;17(3):94-6.
19. Nutescu E. Use of low molecular weight heparin in patients on long term warfarin therapy undergoing minor outpatient surgery or dental surgery. Chicago: University of Illinois at Chicago Medical Center; 2000.
20. Kuwada SK, Balm R, Gostout CJ. The risk of withdrawing chronic anticoagulation because of acute GI bleeding. Am J Gastroenterol 1996;91(6):1116-9.
21. Poller L, Thomson J. Evidence for 'rebound' hypercoagulability after stopping anticoagulants. Lancet 1964;2:62-4.
22. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants: a prospective study. Thromb Haemost 1994;72:222-6.
23. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-83.
24. Blinder D, Manor Y, Martinowitz U, Taicher S. Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INK value with occurrence of postoperative bleeding. Int J Oral Maxillofac Surg 2001;30:518-1.
25. Bailey BM, Fordyce AM. Complications of dental extractions in patients receiving warfarin anticoagulant therapy: a controlled clinical trial. Br Dent J 1983;155:308-10.
26. Benoliel R, Leviner E, Katz J, Tzukert A. Dental treatment for the patient on anticoagulant therapy: prothrombin time value-what difference does it make? Oral Surg Oral Med Oral Pathol 1986;62: 149-51.
27. Souto JC, Oliver A, Zuazu-Jausoro I, Vives A, Fontcuberta J. Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study. J Oral Maxillofac Surg 1996;54:27-32.
28. Herman WW, Konzelman JL Jr, Sutley SH. Current perspectives on dental patients receiving coumarin anticoagulant therapy. JADA 1997;128:327-35.
29. Wahl MJ. Myth of dental surgery in patients receiving anticoagulant therapy. JADA 2000;131:77-81.
30. Guerra L, Balda I, Malcorra JJ. Low-molecular weight heparins in dental extractions of patients receiving oral anticoagulation treatment [in Spanish]. Sangre (Barc) 1995:40(4):336-7.
31. McElwee NE, Johnson ER. Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes. Am J Cardiol 1997;80(4A):39B-43B.